INMB on Nasdaq

Inmune Bio, Inc.

Inmune Bio, Inc. is a focus of CORDStrom.1 It is headquartered in Boca Raton, Florida.1 Its shares trade on Nasdaq under the symbol INMB.1

Price unavailable

Last updated Oct 20, 2026.

Overview

Compare with Calidi Biotherapeutics, Inc., BioCardia, Inc. or Entera Bio Ltd., or pick any stock.

  • TickerINMB on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersBoca Raton, Florida1
  • Incorporated inNV2
  • Business address225 Ne Mizner Blvd, Suite 640, Boca Raton, Fl 334322
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

The only approved products to date are topical and do not address the systemic issues of the disease, which is the focus of CORDStrom.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-94766.0%Operating margin5
-91866.0%Net margin5
257.1%Revenue growth, 20255
-195.3%Return on equity5
-$23.6MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢$20.7M

Out of $50.0K in revenue.5 The company lost money this year.

Financial statements

Revenue67895$50.0K in 2025+355% since 2020
0$100.0K$200.0K$300.0K$400.0K2020: $11.0K$11.0K20202021: $181.0K$181.0K2021+1545%2022: $374.0K$374.0K2022+107%2023: $155.0K$155.0K2023−59%2024: $14.0K$14.0K2024−91%2025: $50.0K$50.0K2025+257%
Operating income1067895-$47.4M in 2025+511% since 2019
-$60.0M-$40.0M-$20.0M02019: -$7.8M-$7.8M20192020: -$12.2M-$12.2M2020+58%2021: -$29.2M-$29.2M2021+138%2022: -$26.0M-$26.0M2022−11%2023: -$29.7M-$29.7M2023+15%2024: -$42.6M-$42.6M2024+43%2025: -$47.4M-$47.4M2025+11%
Net income1067895-$45.9M in 2025+498% since 2019
-$60.0M-$40.0M-$20.0M02019: -$7.7M-$7.7M20192020: -$12.1M-$12.1M2020+58%2021: -$30.3M-$30.3M2021+151%2022: -$27.3M-$27.3M2022−10%2023: -$30.0M-$30.0M2023+10%2024: -$42.1M-$42.1M2024+40%2025: -$45.9M-$45.9M2025+9%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
REVENUE$50.0K$14.0K
General and administrative$10.3M$9.5M
Research and development$20.7M$33.2M
Impairment of acquired in-process research and development intangible assets$16.5M
Total operating expenses$47.4M$42.6M
LOSS FROM OPERATIONS-$47.4M-$42.6M
OTHER INCOME, NET$1.4M$553.0K
NET LOSS-$45.9M-$42.1M
Net loss per common share basic (in Dollars per share)-$1.86-$2.11
Net loss per common share diluted (in Dollars per share)-$1.86-$2.11
Weighted average number of common shares outstanding basic (in Shares)24.8M shares19.9M shares
Weighted average number of common shares outstanding diluted (in Shares)24.8M shares19.9M shares
Gain (loss) on foreign currency translation-$162.0K$224.0K
Total comprehensive loss-$46.1M-$41.9M

Compare Inmune Bio, Inc. with another company

Corporate structure

Inmune Bio, Inc. sits at the top of its group. 3 entities, 3 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Inmune Bio, Inc.

  • CVI Investments, Inc. Filed SCHEDULE 13G/A on Inmune Bio, Inc., latest Aug 14, 2025 (2 filings since Jul 2, 2025)
  • HIGHBRIDGE CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G/A on Inmune Bio, Inc., latest Aug 14, 2025 (2 filings since Oct 25, 2024)
  • Praetorian PR LLC Filed SCHEDULE 13G/A on Inmune Bio, Inc., latest Aug 14, 2025 (3 filings since Jan 15, 2025)
  • Xencor Inc Filed SC 13G/A on Inmune Bio, Inc., latest Oct 2, 2024
  • David J. Moss Filed SC 13D/A on Inmune Bio, Inc., latest Apr 21, 2022
  • Mark William Lowdell Filed SC 13D/A on Inmune Bio, Inc., latest Apr 21, 2022
  • Raymond Joseph Tesi Filed SC 13D/A on Inmune Bio, Inc., latest Apr 21, 2022
  • Altium Capital Management LLC Filed SC 13G/A on Inmune Bio, Inc., latest Feb 14, 2022
  • Inmune Bio, Inc. Boca Raton, Florida
    • INmune Bio Australia Pty Ltd Subsidiary · Australia
    • INmune Bio International Ltd. Subsidiary · United Kingdom

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Inmune Bio, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Machinery and equipment$1.0M5 Dec 31, 2025
Accumulated depreciation$87.0K5 Dec 31, 2025
Property and equipment, net$955.0K5 Dec 31, 2025
Operating-lease assets (leased space)$914.0K5 Dec 31, 2025$307.0K5 Dec 31, 2024+197.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$24.8M5 Dec 31, 2025$20.9M5 Dec 31, 2024+18.3%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$16.5M5 Dec 31, 2024$16.5M9 Dec 31, 20230%

Properties, in its own words

The Company leases approximately 5,000 square feet of office space in Boca Raton, Florida from a third-party, which serves as the headquarters of the Company. We currently pay approximately $16,000 per month for this lease which expires in March 2027.

The Company’s wholly-owned subsidiary, INmune Bio International Ltd leases manufacturing space in the United Kingdom pursuant to a 2-year collaboration agreement in which the Company is required to pay 225,000 pounds for manufacturing space in the first year and 450,000 pounds in the second year. The Company occupies 184 square meters for the production of CORDStrom.

The rest of Item 2

We believe our current facilities are suitable and adequate to meet our current needs.

Item 2 of the 10-K filed Mar 30, 2026.4

Leadership

Who has led Inmune Bio, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Raymond Joseph Tesi2019–2024

Chair

  1. Raymond Joseph Tesi2019

President

  1. Raymond Joseph Tesi2019–2024

Chief financial officer

  1. Cory Randall Ellspermann2025–now
20202025
Board members and other officers (9)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • INmune Bio Australia Pty Ltd Australia3
  • INmune Bio International Ltd. England3

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Timeline

  1. Sep 14, 20268-K Executive or director change; Other events24
  2. Jul 31, 20268-K Other events25
  3. Jul 1, 20268-K Entered a material agreement26
  4. Jun 23, 20268-K Other events27
  5. Jun 17, 20268-K Executive or director change; Shareholder vote28
  6. Jun 2, 20268-K Other events29
  7. May 14, 20268-K Other events30
  8. May 5, 20268-K Entered a material agreement; Regulation FD disclosure31
  9. Feb 27, 20268-K Regulation FD disclosure32
  10. Feb 23, 20268-K Other events33
  11. Feb 19, 20268-K Other events34
  12. Feb 13, 20268-K Regulation FD disclosure35
  13. Feb 8, 2019New chief executive Raymond Joseph Tesi becomes CEO13

Calendar

Coming up

  1. Oct 29, 2026Reports results for the quarter ending Sep/202636

When it reported results

  1. Oct 30, 2025Reported quarterly or annual results37
  2. Aug 7, 2025Reported quarterly or annual results38
  3. May 8, 2025Reported quarterly or annual results39
  4. Mar 27, 2025Reported quarterly or annual results40
  5. Nov 1, 2024Reported quarterly or annual results41
  6. Aug 2, 2024Reported quarterly or annual results42
  7. May 13, 2024Reported quarterly or annual results43
  8. Mar 29, 2024Reported quarterly or annual results44

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

306 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 154 major events, 80 insider forms, 14 large holders, 37 other. The latest 20:

  1. Sep 23, 20264 EDGAR
  2. Sep 23, 20263 EDGAR
  3. Sep 17, 20264 OWNERSHIP DOCUMENT EDGAR
  4. Sep 16, 20263 OWNERSHIP DOCUMENT EDGAR
  5. Sep 14, 20268-K CURRENT REPORT EDGAR
  6. Aug 6, 202610-Q QUARTERLY REPORT EDGAR
  7. Jul 31, 20268-K CURRENT REPORT EDGAR
  8. Jul 7, 20264 EDGAR
  9. Jul 7, 20264 EDGAR
  10. Jul 7, 20264 EDGAR
  11. Jul 1, 20268-K CURRENT REPORT EDGAR
  12. Jun 23, 20268-K CURRENT REPORT EDGAR
  13. Jun 17, 20268-K CURRENT REPORT EDGAR
  14. Jun 2, 20268-K CURRENT REPORT EDGAR
  15. May 14, 20268-K CURRENT REPORT EDGAR
  16. May 7, 202610-Q QUARTERLY REPORT EDGAR
  17. May 5, 20268-K CURRENT REPORT EDGAR
  18. Apr 23, 2026DEF 14A PROXY STATEMENT EDGAR
  19. Mar 30, 202610-K ANNUAL REPORT EDGAR
  20. Feb 27, 20268-K CURRENT REPORT EDGAR

The 306 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

25 open-market trades by officers, directors and large owners since October 2021: 14 buys and 11 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 30, 2024Moss David JChief Executive OfficerBuy10,000$5.29$52.9KForm 4
Sep 12, 2024Tesi Raymond JosephPresident and CEOBuy15,380$6.38$98.1KForm 4
Sep 12, 2024Moss David JChief Executive OfficerBuy7,690$6.38$49.1KForm 4
Jun 25, 2024Juda ScottDirectorBuy5,000$7.27$36.4KForm 4
Apr 19, 2024Moss David JChief Executive OfficerBuy18,028$8.32$150.0KForm 4
Apr 19, 2024Tesi Raymond JosephPresident and CEOBuy18,028$8.32$150.0KForm 4
Apr 19, 2024Lowdell Mark WilliamChief Scientific OfficerBuy14,423$8.32$120.0KForm 4
Apr 19, 2024Juda ScottDirectorBuy29,603$8.32$246.3KForm 4
Nov 10, 2023Juda ScottDirectorBuy7,000$6.95$48.6KForm 4
Jul 12, 2023Schroeder Timothy jDirectorSale10,000$11.01$110.1KForm 4
Mar 17, 2023Moss David JChief Executive OfficerBuy2,500$6.43$16.1KForm 4
May 27, 2022Moss David JChief Executive OfficerBuy3,000$6.79$20.4KForm 4
May 26, 2022Tesi Raymond JosephPresident and CEOBuy6,300$6.41$40.4KForm 4
May 26, 2022Moss David JChief Executive OfficerBuy7,700$6.27$48.3KForm 4
Nov 17, 2021Juda ScottDirectorBuy2,500$13.55$33.9KForm 4
Nov 3, 2021Lowdell Mark WilliamChief Scientific OfficerSale701$20.00$14.0KForm 4
Nov 3, 2021Moss David JChief Executive OfficerSale1,025$20.00$20.5KForm 4
Nov 3, 2021Tesi Raymond JosephPresident and CEOSale3,626$20.00$72.5KForm 4
Oct 27, 2021Tesi Raymond JosephPresident and CEOSale6,517$20.00$130.3KForm 4
Oct 27, 2021Lowdell Mark WilliamChief Scientific OfficerSale2,357$20.00$47.1KForm 4

All 25 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Raymond J. Tesi$486.1K$2.8M53
2025David J. Moss56$416.3K$1.8M53
2025Mark Lowdell,64$66.3K$1.5M53
2025Cory Ellspermann53$190.9K$619.2K53
2024M.D., former CEOPresident and CMO$513.6K$3.0M53
2024CEO and President$405.3K$2.7M53
2024CSO$1.5M$1.8M53

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 83. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Vanguard Capital Management LLC706,424$1.2M0.0%+19,409
Aqr Capital Management LLC662,218$1.1M0.0%+391,901
BlackRock, Inc.311,613$507.9K0.0%−882,499
Raymond James Financial Inc212,995$347.2K0.0%+9,750
Geode Capital Management, LLC190,215$310.3K0.0%−304,754
Goldman Sachs Group Inc185,245$301.9K0.0%−46,341
Millennium Management LLC159,559$260.1K0.0%New
Susquehanna International Group, Llp158,452$258.3K0.0%−35,939
Jane Street Group, LLC134,232$218.8K0.0%+83,288
UBS Group AG110,413$180.0K0.0%−142,927
Westside Investment Management, Inc.108,300$176.5K0.0%No change
Citadel Advisors LLC106,231$173.2K0.0%New
Vanguard Fiduciary Trust Co104,775$170.8K0.0%−18,409
State Street Corp93,363$152.2K0.0%−197,516
Ieq Capital, LLC82,385$134.3K0.0%+57,822
Laird Norton Wetherby Trust Company, LLC52,000$84.8K0.0%+2,000
Focus Partners Advisor Solutions, LLC43,556$71.0K0.0%+531
PNC Financial Services Group, Inc.42,638$69.5K0.0%+2,518
Qube Research & Technologies Ltd40,773$66.5K0.0%New
Mariner, LLC40,320$65.7K0.0%+21,277
Northern Trust Corp37,670$61.4K0.0%−146,555
XTX Topco Ltd35,461$57.8K0.0%+5,155
Fmr LLC33,689$54.9K0.0%+20,099
Cerity Partners LLC33,230$54.2K0.0%+19,188
Renaissance Technologies LLC29,700$48.4K0.0%+12,700

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Inmune Bio, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARInmune Bio, Inc.1
  • CIK0001711754
  • Employer ID (EIN)47-52058354
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inNevada4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address225 Ne Mizner Blvd, Suite 640, Boca Raton, FL 334321
  • Phone85896437201
  • Shares outstanding27,753,789 as of Aug 6, 202612
  • Public float$51.0M as of Jun 30, 20254
  • AuditorCBIZ CPAs P.C., Houston, Texas PCAOB ID 199; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceJul 13, 20171
  • Filings597 in all: 8-K (283), 4 (119), 10-Q (23), CORRESP (15), UPLOAD (15), 3 (14), 424B5 (14), 4/A (9)1
    All 39 form types

    DEF 14A (9), EFFECT (9), 10-K (8), SC 13D/A (6), 424B3 (5), 8-A12B/A (5), 8-K/A (5), S-3 (5), SC 13G (5), SC 13G/A (5), FWP (4), S-8 (4), SCHEDULE 13G/A (4), DRSLTR (3), S-1 (3), S-1/A (3), SC 13D (3), 8-A12B (2), D (2), DRS/A (2), PRE 14A (2), SCHEDULE 13G (2), 10-K/A (1), 144 (1), CERT (1), DEFA14A (1), DEFR14A (1), DRS (1), POS AM (1), S-3/A (1), S-8 POS (1)

  • Latest filingsAnnual report (10-K) Mar 30, 2026
    Quarterly report (10-Q) Aug 6, 2026
    Proxy statement (DEF 14A) Apr 23, 2026
    Latest 8-K (8-K) Sep 14, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock ($0.001 par value)INMBNasdaq

From the cover page of the 10-K filed Mar 30, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks Inmune Bio, Inc. names in Item 1A of its 10-K filed Mar 30, 2026: 54 risks under these headings, as written.4

  • RISKS RELATED TO OUR BUSINESS
  • There is a Substantial Doubt About Our Ability to Continue as a Going Concern
  • We Have a History of Losses and May Never Achieve or Sustain Profitability
  • Limitations on Capital Raising Due to Low Public Float
  • We face intense competition in the markets targeted by our product candidates. Many competitors have substantially greater resources, and all of our product candidates are expected to face strong competition from existing and future drugs.
  • Competition and Technological Change Could Reduce the Attractiveness of Our Product Candidates
  • We are substantially dependent on the success of CORDStrom, and we may never obtain regulatory approval.
  • Global economic uncertainty and financial market volatility caused by political instability, changes in international trade relationships and conflicts, such as the conflict between Russia and Ukraine and the recent military conflict in the Middle East involving Iran, could make it more difficult for us to access financing and could adversely affect our business and operations.
  • Even if we commercialize our product candidates, pricing, reimbursement, and healthcare regulations could limit their market success.
  • We are subject to extensive government regulations.
  • If we cannot keep pace with rapid technological changes or compete effectively, we may not operate profitably.
  • We may request priority review, but the FDA may not grant it, and even if granted, it may not accelerate approval.
The other 43 risks
  • If we are unable to obtain accelerated approval or other expedited regulatory designations, development and commercialization of our product candidates may be delayed or more costly.
  • Clinical drug development is lengthy, expensive, and inherently uncertain, and our product candidates may never receive regulatory approval.
  • Preclinical and early-stage clinical trial results may not predict later results, and interim or preliminary data may change materially.
  • If clinical trials fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities, we may incur additional costs, experience delays, or be unable to commercialize our product candidates.
  • Unforeseen events in clinical trials could delay or prevent marketing approval of our product candidates.
  • Regulatory Approval of Product Brand Names
  • Risk of Noncompliance with Regulatory Requirements
  • Even if our product candidates are approved, they may fail to achieve sufficient market acceptance, which could limit revenue and affect our business.
  • Even if we obtain regulatory approvals for CORDStrom or any product, ongoing regulation may limit our ability to manufacture and commercialize these products.
  • If our product candidates are approved and later found to be less effective than expected or to cause previously unidentified side effects, our business could be materially harmed.
  • Even if we obtain marketing approval for a product candidate, we will remain subject to extensive ongoing regulatory requirements, and failure to comply could materially harm our business.
  • We currently have no marketing or sales organization, and our inability to establish these capabilities or collaborate with third parties could limit our product revenue.
  • We face substantial competition from other pharmaceutical and biotechnology companies and our operating results may suffer if we fail to compete effectively.
  • Dependence on Key Personnel
  • Product liability claims could result in substantial costs, divert resources, and limit the development or commercialization of our product candidates.
  • We will need to expand our organization and may encounter challenges in managing this growth.
  • Our manufacturing processes are complex and subject to numerous risks that could increase costs and limit the supply of our drug candidates.
  • We and our contract manufacturers are subject to extensive regulatory requirements with respect to the manufacture of our product candidates, and any failure to comply with these requirements could materially harm our business.
  • Risk Related to Hazardous and Biological Materials
  • We rely on third parties to conduct and support clinical trials for our product candidates, and any failure by these parties to meet their obligations could materially delay or impair our development programs and regulatory approvals.
  • Current and future healthcare reform measures and pricing regulations may increase the difficulty and cost of commercializing our product candidates and may materially reduce the prices we may obtain and the revenues we may generate if any of our product candidates are approved.
  • The regulatory approval processes of the FDA, EMA, and other comparable foreign regulatory authorities are complex, time-consuming and inherently unpredictable. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for CORDStrom, we may not be able to commercialize, or may be delayed in commercializing, CORDStrom, and our ability to generate revenue will be materially impaired.
  • Deterioration in general economic conditions in the United States, Canada and globally, including the effect of prolonged periods of inflation on our suppliers, third-party service providers and potential partners, could harm our business and results of operations.
  • Public health emergencies or other widespread health events could adversely affect our operations and financial results.
  • We are exposed to risks related to currency exchange rates.
  • Our employees, principal investigators, consultants, and collaborators may engage in misconduct or fail to comply with regulatory requirements, which could result in liability and harm our reputation.
  • Cybersecurity Incidents and Other Technological Disruptions Could Negatively Affect Our Business and Customer Relationships
  • Use of Social Media Platforms Presents New Risks
  • The use or anticipated use of artificial intelligence, or AI, technologies, including generative AI, by us or third parties, may increase or create new operational risks.
  • The U.S. Congress, the Trump administration, or any new administration may make substantial changes to fiscal, tax, and other federal policies that may adversely affect our business.
  • Disruptions at the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner, or otherwise prevent those agencies from performing normal business functions, which could negatively impact our business and our timelines.
  • Risks Related to our Intellectual Property
  • We depend on obtaining certain patents and protecting our proprietary rights.
  • If we fail to protect our intellectual property rights, our ability to pursue the development of our technologies and products would be negatively affected.
  • By working with research collaborators patent rights may be jointly owned by different parties.
  • Risks related to government-funded intellectual property.
  • We license our patents from others. If such owners do not properly maintain or enforce the intellectual property underlying such licenses, our competitive position and business prospects could be harmed. Our licensors may also seek to terminate our license.
  • We are dependent on our licensing agreement with Xencor, and the termination of this agreement would harm our business.
  • Potential conflict of interest with our INKmune license.
  • Changes in patent laws could diminish the value of our intellectual property and impair our ability to protect our products.
  • Risks Related to our Common Stock
  • We may fail to qualify for continued listing on The NASDAQ Capital Market which could make it more difficult for investors to sell their shares.
  • We do not intend to pay dividends in the foreseeable future.
  • Compliance with federal securities laws and reporting requirements is costly and may divert resources from growth initiatives.
  • Our stock price may be volatile.
  • You may have difficulty trading and obtaining quotations for our common stock.
  • Additional stock offerings in the future may dilute your ownership interest in our company.
  • Our internal control over financial reporting may not meet the standards required by Section 404 of the Sarbanes-Oxley Act, and failure to achieve or maintain effective internal controls could adversely affect our business and stock price.
  • Anti-takeover provisions in our stockholder rights plan could make a third-party acquisition more difficult.
  • Sales of our common stock by employees, including executive officers, could cause the trading price of our common stock to decline and may be viewed negatively by investors.

Legal proceedings

We currently are not a party to any material litigation or other material legal proceedings. We may, from time to time, be subject to legal proceedings and claims arising in the normal course of business.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
    SEC EDGAROther events
  26. 26
  27. 27
    SEC EDGAROther events
  28. 28
  29. 29
    SEC EDGAROther events
  30. 30
    SEC EDGAROther events
  31. 31
  32. 32
  33. 33
    SEC EDGAROther events
  34. 34
    SEC EDGAROther events
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53